pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK
Nektar Therapeutics UK Limited
Nektar Therapeutics is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker NKTR. Primary therapeutic focus areas include Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneum
455 Mission Bay Boulevard South, San Francisco, California 94158, US HQ
1990 Founded
610 Employees
Public company Type
NKTR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 455 Mission Bay Boulevard South, San Francisco, California 94158, US
- Founded
- 1990
- Employees
- 610
- Programs
- 57
- Drugs
- 31
- Patents
- 423
NKTR-255
Phase 2 · small molecule · Head and Neck Squamous Cell Carcinoma
NKTR-255 for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Nektar Therapeutics UK Limited with 1 ClinicalTrials.gov record(s).
Internal code 19-255-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nektar Therapeutics UK Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Head and Neck Squamous Cell Carcinoma
- Status
- completed
- Trials
- 1